23:28 , Jul 13, 2018 |  BC Extra  |  Preclinical News

RXR a potential minimal residual disease target in melanoma

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma. Cancer relapse is driven by MRD,...
07:00 , Jun 9, 2016 |  BC Innovations  |  Translation in Brief

Cell by cell

Although it's well-established that individual cancer cells can harbor mutations that help them resist therapy, researchers have just begun looking at how non-genetic variations can affect treatment outcomes. A team of scientists from the Broad...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: AXL receptor tyrosine kinase (AXL; UFO); BRAF; MEK; microphthalmia-associated transcription factor (MITF)

Cancer INDICATION: Melanoma In vitro studies suggest AXL inhibitors could help sensitize melanoma cells that express low levels of MITF to targeted therapies. In treatment-naive melanoma cell lines, low MITF expression was associated with increased resistance to...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma BRAF; MEK; microphthalmia-associated transcription factor (MITF); histone deacetylase (HDAC) Cell culture and mouse studies suggest combining...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Low-copy piggyBac (PB) mutagenesis screening to identify mutated genes that drive cancer Low-copy PB screening in mice could...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Microphthalmia-associated transcription factor (MITF); hypoxia-inducible factor 1 (HIF1) Patient sample and...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Microphthalmia-associated transcription factor...
08:00 , Jan 22, 2009 |  BC Innovations  |  Tools & Techniques

Bead-based kinase profiling

A team of researchers from the Broad Institute and other institutions has developed a high throughput screening method to profile activated tyrosine kinases in cancer cells.1 The group applied the approach to glioblastoma multiforme and...